Cargando…

Brusatol Enhances the Chemotherapy Efficacy of Gemcitabine in Pancreatic Cancer via the Nrf2 Signalling Pathway

Although gemcitabine is the standard chemotherapy treatment for advanced pancreatic cancer, its benefits are quite limited due to prevalent chemoresistance, and the mechanism underlying gemcitabine chemoresistance remains unclear. Currently, Nrf2 has been deemed as a significant contributor to gemci...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiang, Yukai, Ye, Wen, Huang, Chaohao, Yu, Dinglai, Chen, Hao, Deng, Tuo, Zhang, Fan, Lou, Bin, Zhang, Jie, Shi, Keqing, Chen, Bicheng, Zhou, Mengtao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5932458/ https://www.ncbi.nlm.nih.gov/pubmed/29849873 http://dx.doi.org/10.1155/2018/2360427

Ejemplares similares

Lipoxin A4 Ameliorates Acute Pancreatitis-Associated Acute Lung Injury through the Antioxidative and Anti-Inflammatory Effects of the Nrf2 Pathway
por: Ye, Wen, et al.
Publicado: (2019)

Quercetin inhibits epithelial–mesenchymal transition, decreases invasiveness and metastasis, and reverses IL-6 induced epithelial–mesenchymal transition, expression of MMP by inhibiting STAT3 signaling in pancreatic cancer cells
por: Yu, Dinglai, et al.
Publicado: (2017)

Dermokine contributes to epithelial–mesenchymal transition through increased activation of signal transducer and activator of transcription 3 in pancreatic cancer
por: Huang, Chaohao, et al.
Publicado: (2017)

Isoorientin induces apoptosis, decreases invasiveness, and downregulates VEGF secretion by activating AMPK signaling in pancreatic cancer cells
por: Ye, Tingting, et al.
Publicado: (2016)

The DNA methylation profile of non-coding RNAs improves prognosis prediction for pancreatic adenocarcinoma
por: Zhang, Jie, et al.
Publicado: (2019)

Brusatol, an NRF2 inhibitor for future cancer therapeutic
por: Cai, Sabrina J., et al.
Publicado: (2019)

Brusatol
por: Hu, Shu-Zhi, et al.
Publicado: (2012)

Downregulation of TNF-α/TNF-R1 Signals by AT-Lipoxin A4 May Be a Significant Mechanism of Attenuation in SAP-Associated Lung Injury
por: Yu, Suhui, et al.
Publicado: (2019)

Screening and Identifying m6A Regulators as an Independent Prognostic Biomarker in Pancreatic Cancer Based on The Cancer Genome Atlas Database
por: Lin, Bi, et al.
Publicado: (2021)

DPP4 Inhibitor Attenuates Severe Acute Pancreatitis-Associated Intestinal Inflammation via Nrf2 Signaling
por: Zhou, Xiang, et al.
Publicado: (2019)

The Nrf2 inhibitor brusatol synergistically enhances the cytotoxic effect of lapatinib in HER2-positive cancers
por: Tian, Ziyin, et al.
Publicado: (2022)

The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer
por: Evans, Jonathan P., et al.
Publicado: (2018)

Natural Compounds, Optimal Combination of Brusatol and Polydatin Promote Anti-Tumor Effect in Breast Cancer by Targeting Nrf2 Signaling Pathway
por: Li, Jing, et al.
Publicado: (2023)

The toxic effects and possible mechanisms of Brusatol on mouse oocytes
por: Ma, Rujun, et al.
Publicado: (2017)

UVA Irradiation Enhances Brusatol-Mediated Inhibition of Melanoma Growth by Downregulation of the Nrf2-Mediated Antioxidant Response
por: Wang, Mei, et al.
Publicado: (2018)

Correction: The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer
por: Evans, Jonathan P., et al.
Publicado: (2019)

TLR3 Ligand PolyI:C Prevents Acute Pancreatitis Through the Interferon-β/Interferon-α/β Receptor Signaling Pathway in a Caerulein-Induced Pancreatitis Mouse Model
por: Huang, Chaohao, et al.
Publicado: (2019)

Brusatol, a Nrf2 Inhibitor Targets STAT3 Signaling Cascade in Head and Neck Squamous Cell Carcinoma
por: Lee, Jong Hyun, et al.
Publicado: (2019)

Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity—implications for therapeutic targeting of Nrf2
por: Olayanju, Adedamola, et al.
Publicado: (2015)

High Glucose-Induced ROS Production Stimulates Proliferation of Pancreatic Cancer via Inactivating the JNK Pathway
por: Luo, Jiao, et al.
Publicado: (2018)

Exploring brusatol as a new anti-pancreatic cancer adjuvant: biological evaluation and mechanistic studies
por: Lu, Zheng, et al.
Publicado: (2017)

Brusatol Inhibits Proliferation and Invasion of Glioblastoma by Down-Regulating the Expression of ECM1
por: Dai, Zhang’an, et al.
Publicado: (2021)

Synergistic antitumor effect of brusatol combined with cisplatin on colorectal cancer cells
por: Chen, Hai-Ming, et al.
Publicado: (2018)

Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway
por: Zhou, Yunjiang, et al.
Publicado: (2019)

HNRNPA2B1 regulates the epithelial–mesenchymal transition in pancreatic cancer cells through the ERK/snail signalling pathway
por: Dai, Shengjie, et al.
Publicado: (2017)

Brusatol Inhibits Tumor Growth and Increases the Efficacy of Cabergoline against Pituitary Adenomas
por: Wu, Zerui, et al.
Publicado: (2021)

Timing of chemotherapy-induced neutropenia: the prognostic factor in advanced pancreatic cancer patients treated with gemcitabine / gemcitabine-based chemotherapy
por: Chen, Yang, et al.
Publicado: (2017)

Inhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabine
por: DUONG, HONG-QUAN, et al.
Publicado: (2013)

Natural Killer Cell-Derived Exosomal miR-3607-3p Inhibits Pancreatic Cancer Progression by Targeting IL-26
por: Sun, Hongwei, et al.
Publicado: (2019)

Corrigendum: Natural Killer Cell-Derived Exosomal miR-3607-3p Inhibits Pancreatic Cancer Progression by Targeting IL-26
por: Sun, Hongwei, et al.
Publicado: (2020)

Brusatol: A potential anti-tumor quassinoid from Brucea javanica
por: Yu, Xiao-qi, et al.
Publicado: (2020)

Redox-sensitive micelles composed of disulfide-linked Pluronic-linoleic acid for enhanced anticancer efficiency of brusatol
por: Zhang, Jinming, et al.
Publicado: (2018)

Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathway
por: Zhang, Juan, et al.
Publicado: (2022)

Calcium channel blockers potentiate gemcitabine chemotherapy in pancreatic cancer
por: Principe, Daniel R., et al.
Publicado: (2022)

Nrf2 Inhibitor, Brusatol in Combination with Trastuzumab Exerts Synergistic Antitumor Activity in HER2-Positive Cancers by Inhibiting Nrf2/HO-1 and HER2-AKT/ERK1/2 Pathways
por: Yang, Yun, et al.
Publicado: (2020)

Larvicidal Activity of Brusatol Isolated from Brucea javanica (L) Merr on Culex quinquefasciatus
por: SUTININGSIH, Dwi, et al.
Publicado: (2019)

PB2168: BRUSATOL INDUCES APOPTOSIS IN AGGRESSIVE LYMPHOMA CELLS IN VITRO AND SYNERGIZES WITH VENETOCLAX
por: Szmyra, M., et al.
Publicado: (2022)

Resected Pancreatic Cancer With N2 Node Involvement Is Refractory to Gemcitabine-Based Adjuvant Chemotherapy
por: Liu, Chen, et al.
Publicado: (2020)

HEATR1 deficiency promotes pancreatic cancer proliferation and gemcitabine resistance by up-regulating Nrf2 signaling
por: Zhou, Yunjiang, et al.
Publicado: (2019)

Antitumor Efficacy of α-Solanine against Pancreatic Cancer In Vitro and In Vivo
por: Lv, Chongqing, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_2gf6hac73pt2lpnv85n9sd726f